

# Direct-acting Antiviral Drugs Market, Global Outlook and Forecast 2022-2028

https://marketpublishers.com/r/D66867B6740AEN.html

Date: January 2022

Pages: 65

Price: US\$ 3,250.00 (Single User License)

ID: D66867B6740AEN

## **Abstracts**

This report contains market size and forecasts of Direct-acting Antiviral Drugs in Global, including the following market information:

Global Direct-acting Antiviral Drugs Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Direct-acting Antiviral Drugs market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

NS3/4A Protease Inhibitors Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Direct-acting Antiviral Drugs include AbbVie Inc., GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Roche, Bristol-Myers Squibb Company and Gilead Sciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Direct-acting Antiviral Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.



Total Market by Segment:

Global Direct-acting Antiviral Drugs Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Direct-acting Antiviral Drugs Market Segment Percentages, by Type, 2021 (%)

NS3/4A Protease Inhibitors

Nucleoside and Nucleotide NS5B Polymerase Inhibitors

**NS5A Inhibitors** 

Non-Nucleoside NS5B Polymerase Inhibitors

Global Direct-acting Antiviral Drugs Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Direct-acting Antiviral Drugs Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

**Ambulatory Surgical Centers** 

**Pharmacies** 

Others


Global Direct-acting Antiviral Drugs Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Direct-acting Antiviral Drugs Market Segment Percentages, By Region and Country, 2021 (%)



North America	
	US
	Canada
	Mexico
Europe	
	Germany
	France
	U.K.
	Italy
	Russia
	Nordic Countries
	Benelux
	Rest of Europe
Asia	
	China
	Japan
	South Korea
	Southeast Asia
	India
	Rest of Asia







Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma



## **Contents**

#### 1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Direct-acting Antiviral Drugs Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Direct-acting Antiviral Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

#### 2 GLOBAL DIRECT-ACTING ANTIVIRAL DRUGS OVERALL MARKET SIZE

- 2.1 Global Direct-acting Antiviral Drugs Market Size: 2021 VS 2028
- 2.2 Global Direct-acting Antiviral Drugs Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

#### **3 COMPANY LANDSCAPE**

- 3.1 Top Direct-acting Antiviral Drugs Players in Global Market
- 3.2 Top Global Direct-acting Antiviral Drugs Companies Ranked by Revenue
- 3.3 Global Direct-acting Antiviral Drugs Revenue by Companies
- 3.4 Top 3 and Top 5 Direct-acting Antiviral Drugs Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Direct-acting Antiviral Drugs Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Direct-acting Antiviral Drugs Players in Global Market
  - 3.6.1 List of Global Tier 1 Direct-acting Antiviral Drugs Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Direct-acting Antiviral Drugs Companies

#### 4 MARKET SIGHTS BY PRODUCT



#### 4.1 Overview

- 4.1.1 by Type Global Direct-acting Antiviral Drugs Market Size Markets, 2021 & 2028
- 4.1.2 NS3/4A Protease Inhibitors
- 4.1.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
- 4.1.4 NS5A Inhibitors
- 4.1.5 Non-Nucleoside NS5B Polymerase Inhibitors
- 4.2 By Type Global Direct-acting Antiviral Drugs Revenue & Forecasts
  - 4.2.1 By Type Global Direct-acting Antiviral Drugs Revenue, 2017-2022
  - 4.2.2 By Type Global Direct-acting Antiviral Drugs Revenue, 2023-2028
- 4.2.3 By Type Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028

#### **5 SIGHTS BY APPLICATION**

#### 5.1 Overview

- 5.1.1 By Application Global Direct-acting Antiviral Drugs Market Size, 2021 & 2028
- 5.1.2 Hospitals
- 5.1.3 Clinics
- 5.1.4 Ambulatory Surgical Centers
- 5.1.5 Pharmacies
- 5.1.6 Others
- 5.2 By Application Global Direct-acting Antiviral Drugs Revenue & Forecasts
  - 5.2.1 By Application Global Direct-acting Antiviral Drugs Revenue, 2017-2022
  - 5.2.2 By Application Global Direct-acting Antiviral Drugs Revenue, 2023-2028
- 5.2.3 By Application Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028

#### **6 SIGHTS BY REGION**

- 6.1 By Region Global Direct-acting Antiviral Drugs Market Size, 2021 & 2028
- 6.2 By Region Global Direct-acting Antiviral Drugs Revenue & Forecasts
- 6.2.1 By Region Global Direct-acting Antiviral Drugs Revenue, 2017-2022
- 6.2.2 By Region Global Direct-acting Antiviral Drugs Revenue, 2023-2028
- 6.2.3 By Region Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- 6.3 North America
  - 6.3.1 By Country North America Direct-acting Antiviral Drugs Revenue, 2017-2028
  - 6.3.2 US Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.3.3 Canada Direct-acting Antiviral Drugs Market Size, 2017-2028



- 6.3.4 Mexico Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.4 Europe
  - 6.4.1 By Country Europe Direct-acting Antiviral Drugs Revenue, 2017-2028
  - 6.4.2 Germany Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.3 France Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.4 U.K. Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.5 Italy Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.6 Russia Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.7 Nordic Countries Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.4.8 Benelux Direct-acting Antiviral Drugs Market Size, 2017-2028

#### 6.5 Asia

- 6.5.1 By Region Asia Direct-acting Antiviral Drugs Revenue, 2017-2028
- 6.5.2 China Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.5.3 Japan Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.5.4 South Korea Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.5.5 Southeast Asia Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.5.6 India Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.6 South America
  - 6.6.1 By Country South America Direct-acting Antiviral Drugs Revenue, 2017-2028
  - 6.6.2 Brazil Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.6.3 Argentina Direct-acting Antiviral Drugs Market Size, 2017-2028
- 6.7 Middle East & Africa
- 6.7.1 By Country Middle East & Africa Direct-acting Antiviral Drugs Revenue, 2017-2028
  - 6.7.2 Turkey Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.7.3 Israel Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.7.4 Saudi Arabia Direct-acting Antiviral Drugs Market Size, 2017-2028
  - 6.7.5 UAE Direct-acting Antiviral Drugs Market Size, 2017-2028

#### **7 PLAYERS PROFILES**

- 7.1 AbbVie Inc.
  - 7.1.1 AbbVie Inc. Corporate Summary
  - 7.1.2 AbbVie Inc. Business Overview
  - 7.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Major Product Offerings
  - 7.1.4 AbbVie Inc. Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.1.5 AbbVie Inc. Key News
- 7.2 **GSK**
- 7.2.1 GSK Corporate Summary



- 7.2.2 GSK Business Overview
- 7.2.3 GSK Direct-acting Antiviral Drugs Major Product Offerings
- 7.2.4 GSK Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
- 7.2.5 GSK Key News
- 7.3 Boehringer Ingelheim
  - 7.3.1 Boehringer Ingelheim Corporate Summary
  - 7.3.2 Boehringer Ingelheim Business Overview
  - 7.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Major Product Offerings
- 7.3.4 Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.3.5 Boehringer Ingelheim Key News
- 7.4 Merck
  - 7.4.1 Merck Corporate Summary
  - 7.4.2 Merck Business Overview
  - 7.4.3 Merck Direct-acting Antiviral Drugs Major Product Offerings
  - 7.4.4 Merck Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.4.5 Merck Key News
- 7.5 Novartis
  - 7.5.1 Novartis Corporate Summary
  - 7.5.2 Novartis Business Overview
  - 7.5.3 Novartis Direct-acting Antiviral Drugs Major Product Offerings
  - 7.5.4 Novartis Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.5.5 Novartis Key News
- 7.6 Beximco Pharmaceuticals
  - 7.6.1 Beximco Pharmaceuticals Corporate Summary
  - 7.6.2 Beximco Pharmaceuticals Business Overview
  - 7.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Major Product Offerings
- 7.6.4 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.6.5 Beximco Pharmaceuticals Key News
- 7.7 Roche
  - 7.7.1 Roche Corporate Summary
  - 7.7.2 Roche Business Overview
  - 7.7.3 Roche Direct-acting Antiviral Drugs Major Product Offerings
  - 7.7.4 Roche Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.7.5 Roche Key News
- 7.8 Bristol-Myers Squibb Company
- 7.8.1 Bristol-Myers Squibb Company Corporate Summary
- 7.8.2 Bristol-Myers Squibb Company Business Overview



- 7.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Major Product Offerings
- 7.8.4 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.8.5 Bristol-Myers Squibb Company Key News
- 7.9 Gilead Sciences
  - 7.9.1 Gilead Sciences Corporate Summary
  - 7.9.2 Gilead Sciences Business Overview
  - 7.9.3 Gilead Sciences Direct-acting Antiviral Drugs Major Product Offerings
- 7.9.4 Gilead Sciences Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
- 7.9.5 Gilead Sciences Key News
- 7.10 Janssen (Johnson & Johnson)
  - 7.10.1 Janssen (Johnson & Johnson) Corporate Summary
  - 7.10.2 Janssen (Johnson & Johnson) Business Overview
- 7.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Major Product Offerings
- 7.10.4 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
  - 7.10.5 Janssen (Johnson & Johnson) Key News
- 7.11 Vertex Pharmaceuticals
  - 7.11.1 Vertex Pharmaceuticals Corporate Summary
  - 7.11.2 Vertex Pharmaceuticals Business Overview
  - 7.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Major Product Offerings
- 7.11.4 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
- 7.11.5 Vertex Pharmaceuticals Key News
- 7.12 Natco Pharma
  - 7.12.1 Natco Pharma Corporate Summary
  - 7.12.2 Natco Pharma Business Overview
  - 7.12.3 Natco Pharma Direct-acting Antiviral Drugs Major Product Offerings
- 7.12.4 Natco Pharma Direct-acting Antiviral Drugs Revenue in Global Market (2017-2022)
- 7.12.5 Natco Pharma Key News

#### 8 CONCLUSION

#### 9 APPENDIX



- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer



## **List Of Tables**

#### LIST OF TABLES

- Table 1. Direct-acting Antiviral Drugs Market Opportunities & Trends in Global Market
- Table 2. Direct-acting Antiviral Drugs Market Drivers in Global Market
- Table 3. Direct-acting Antiviral Drugs Market Restraints in Global Market
- Table 4. Key Players of Direct-acting Antiviral Drugs in Global Market
- Table 5. Top Direct-acting Antiviral Drugs Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Direct-acting Antiviral Drugs Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Direct-acting Antiviral Drugs Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Direct-acting Antiviral Drugs Product Type
- Table 9. List of Global Tier 1 Direct-acting Antiviral Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Direct-acting Antiviral Drugs Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type Global Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type Direct-acting Antiviral Drugs Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type Direct-acting Antiviral Drugs Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application Global Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application Direct-acting Antiviral Drugs Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application Direct-acting Antiviral Drugs Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region Global Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region Global Direct-acting Antiviral Drugs Revenue (US\$, Mn), 2017-2022
- Table 19. By Region Global Direct-acting Antiviral Drugs Revenue (US\$, Mn), 2023-2028
- Table 20. By Country North America Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2022
- Table 21. By Country North America Direct-acting Antiviral Drugs Revenue, (US\$,



Mn), 2023-2028

Table 22. By Country - Europe Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2023-2028

Table 30. AbbVie Inc. Corporate Summary

Table 31. AbbVie Inc. Direct-acting Antiviral Drugs Product Offerings

Table 32. AbbVie Inc. Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 33. GSK Corporate Summary

Table 34. GSK Direct-acting Antiviral Drugs Product Offerings

Table 35. GSK Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 36. Boehringer Ingelheim Corporate Summary

Table 37. Boehringer Ingelheim Direct-acting Antiviral Drugs Product Offerings

Table 38. Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 39. Merck Corporate Summary

Table 40. Merck Direct-acting Antiviral Drugs Product Offerings

Table 41. Merck Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 42. Novartis Corporate Summary

Table 43. Novartis Direct-acting Antiviral Drugs Product Offerings

Table 44. Novartis Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 45. Beximco Pharmaceuticals Corporate Summary

Table 46. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Offerings

Table 47. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)

Table 48. Roche Corporate Summary

Table 49. Roche Direct-acting Antiviral Drugs Product Offerings



- Table 50. Roche Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)
- Table 51. Bristol-Myers Squibb Company Corporate Summary
- Table 52. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Offerings
- Table 53. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)
- Table 54. Gilead Sciences Corporate Summary
- Table 55. Gilead Sciences Direct-acting Antiviral Drugs Product Offerings
- Table 56. Gilead Sciences Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)
- Table 57. Janssen (Johnson & Johnson) Corporate Summary
- Table 58. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product Offerings
- Table 59. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)
- Table 60. Vertex Pharmaceuticals Corporate Summary
- Table 61. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Offerings
- Table 62. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)
- Table 63. Natco Pharma Corporate Summary
- Table 64. Natco Pharma Direct-acting Antiviral Drugs Product Offerings
- Table 65. Natco Pharma Direct-acting Antiviral Drugs Revenue (US\$, Mn), (2017-2022)



# **List Of Figures**

#### LIST OF FIGURES

- Figure 1. Direct-acting Antiviral Drugs Segment by Type in 2021
- Figure 2. Direct-acting Antiviral Drugs Segment by Application in 2021
- Figure 3. Global Direct-acting Antiviral Drugs Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Direct-acting Antiviral Drugs Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Direct-acting Antiviral Drugs Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2021
- Figure 8. By Type Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 9. By Application Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 10. By Region Global Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 11. By Country North America Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 12. US Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country Europe Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 16. Germany Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region Asia Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 24. China Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028



- Figure 28. India Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country South America Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 30. Brazil Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country Middle East & Africa Direct-acting Antiviral Drugs Revenue Market Share, 2017-2028
- Figure 33. Turkey Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 34. Israel Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 35. Saudi Arabia Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 36. UAE Direct-acting Antiviral Drugs Revenue, (US\$, Mn), 2017-2028
- Figure 37. AbbVie Inc. Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 38. GSK Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 39. Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 40. Merck Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 41. Novartis Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 42. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 43. Roche Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 44. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 45. Gilead Sciences Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 46. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 47. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 48. Natco Pharma Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



## I would like to order

Product name: Direct-acting Antiviral Drugs Market, Global Outlook and Forecast 2022-2028

Product link: <a href="https://marketpublishers.com/r/D66867B6740AEN.html">https://marketpublishers.com/r/D66867B6740AEN.html</a>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/D66867B6740AEN.html">https://marketpublishers.com/r/D66867B6740AEN.html</a>